In January 2023, the Brukinsa, a next-generation BTK inhibitor, received FDA approval for chronic lymphocytic leukemia (CLL).

Berry softball coach Darrell Thomas leads team into North Regional next week while undergoing chemotherapy treatments.

Heidi Shupe has a myriad of medals proudly displayed in her home. But 20 years ago, her life looked a lot different.

China’s NMPA has approved InnoCare Pharma’s orelabrutinib for use as a first-line treatment for CLL and small lymphocytic ...

ScaleReady, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation and CellReady, today announced that March ...

Researchers sought to assess the access to CAR-T therapy for patients within community-based and transplant cell therapy networks.

Q1 2025 earnings reveal Adaptive Biotechnologies' 34% MRD revenue growth, improved margins, and raised guidance.

High-dose chemotherapy and HSCT can provide long-term benefits in patients with MCL, a retrospective study suggests.

China NMPA approves InnoCare Pharma’s orelabrutinib for first-line treatment of patients with CLL/SLL: Beijing Monday, April 28, 2025, 12:00 Hrs [IST] InnoCare Pharma, a leading ...

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

follicular lymphoma marginal zone lymphoma mantle cell lymphoma anemia that’s caused by myelodysplastic syndrome multiple myeloma Revlimid belongs to a class of drugs called thalidomide analogues.